Long-term follow-up of a RCT | P2Y12 inhibitor monotherapy vs. DAPT after percutaneous coronary intervention.

Long-term Effects of P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention: 3-Year Follow-up of the SMART-CHOICE Randomized Clinical Trial – JAMA Cardiology (link to abstract – $ for full-text)

Original Study: Randomized Trials: Shorter Duration of Dual Antiplatelet Therapy May be an Option for Patients Undergoing Percutaneous Coronary Intervention

Commentary on Twitter

In #RCT follow-up, P2Y12 inhibitor monotherapy after 3 months of DAPT found to be comparable with prolonged DAPT for preventing ischemic events. P2Y12 inhibitor monotherapy resulted in significantly lower rate of major bleeding for up to 3 yrs. https://t.co/pBv9X87lEg #Research pic.twitter.com/42Y28hPPT2

— JAMA Cardiology (@JAMACardio) September 30, 2022